Morepen LaboratoriesNSE:MOREPENLAB +0.43%79 Debt-to-EBITDA is 1.58 as of Mar. 2026, which is 732% above its 10-year median of 0.19. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 79/100 and a GF Value™ of ₹49.95 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 690 Drug Manufacturers companies, Morepen Laboratories ranks better than 57.97% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Morepen Laboratories's Debt-to-EBITDA or its related term are showing as below:
NSE:MOREPENLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.12 Med: 0.19 Max: 1.2
Current: 1.2
During the past 13 years, the highest Debt-to-EBITDA Ratio of Morepen Laboratories was 1.20. The lowest was 0.12. And the median was 0.19.
NSE:MOREPENLAB's Debt-to-EBITDA is ranked better than 57.97% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs NSE:MOREPENLAB: 1.20
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Morepen Laboratories Debt-to-EBITDA Related Terms
Morepen Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Morepen Laboratories (NSE:MOREPENLAB) has a Debt-to-EBITDA of 1.58 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Morepen Laboratories. This is 732% above median its historical median of 0.19. Over the past decade, Morepen Laboratories' Debt-to-EBITDA has ranged from 0.12 to 1.20. According to the industry distribution chart, Morepen Laboratories ranks #290 out of 690 companies in the Drug Manufacturers industry, placing it in the top 42%.
Is Morepen Laboratories' Debt-to-EBITDA too high?
Morepen Laboratories' current Debt-to-EBITDA of 1.58 is 732% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.20. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Morepen Laboratories' value of 1.58 is 5.4% below this industry median. Based on the distribution chart, Morepen Laboratories ranks #290 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #290 out of 690 companies for Debt-to-EBITDA. This puts Morepen Laboratories in the upper half of its industry. The industry median Debt-to-EBITDA is 1.67. Morepen Laboratories' value of 1.58 is 5.4% below this benchmark. Historically, Morepen Laboratories' own Debt-to-EBITDA has ranged from 0.12 to 1.20 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.67, Morepen Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current Debt-to-EBITDA of 1.58 is 5.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Morepen Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current Debt-to-EBITDA is 1.58, which is 732% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.95, compared to a current price of ₹61.22 — trading 22.6% above its estimated fair value. The current Debt-to-EBITDA is 1.58, which is 732% above median its 10-year median of 0.19 and 5.4% below the Drug Manufacturers industry median of 1.67. Morepen Laboratories' overall GF Score™ is 79/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Debt-to-EBITDA is 1.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹61.22 is trading 22.6% above its estimated GF Value™ of ₹49.95.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
Debt-to-EBITDA: 1.58 (732% above median its 10-year median of 0.19)
GF Value™: ₹49.95 vs. price of ₹61.22 (22.6% above fair value)
Industry Position: 5.4% below the Drug Manufacturers median (#290 of 690)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
79GF Score
Get the complete analysis for NSE:MOREPENLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
